Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
BOJ Hawk Signals Faster Interest Rate Hikes Amid Inflation Risks 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
